Adult diffuse glioma: including astrocytoma, IDH-mutant
Conditions
Interventions
KPS less than 70:NA
KPS more than 70:NA
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Pathologically diagnosed adult diffuse glioma patients( including astrocytoma, IDH-mutant;oligodendroglioma, IDH-mutant and1p/19qcodeleted;glioblastoma, IDH-wildtype;other adult diffuse glioma NEC/ NOS). 2.For newly diagnosed patients, the patient has not received the first nonsurgical treatment. 3.For recurrent patients, the patient has not received the first non-surgical treatment after the recurrence. 4.No significant cognitive impairment based on researchers' judgment. 5.Patients can use mobile phones or computers on their own or with the help of others, read and understand Chinese, at least with primary school culture. 6.Patients are undergoing anti-tumor treatment and continue to receive treatment within the next 28 days. 7.Patients sign written informed consent. 8.18 to 85 years old.
Exclusion criteria
Exclusion criteria: 1.Patients who are not considered suitable for this study. 2.Since the diagnosis, the patient has undergone non-surgical treatment. 3.Patients fail to complete the questionnaire within 42 days of signing informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The customized PRO-CTCAE ;The Patient Global Impression of Change; | — |
Secondary
| Measure | Time frame |
|---|---|
| ClinRO CTCAE (Contains only the customized PRO-CTCAE scale's terms);The customized PRO-CTCAE (out-of-order version);QLQ-C30 ;KPS score; | — |
Countries
China
Contacts
Public ContactWu Jinsong
Huashan Hospital, Fudan University
Outcome results
None listed